Tampa Bay residents may be eligible to participate in one of the nation’s largest clinical trials for COVID treatments via Tampa General.
TGH and USF Health plan to serve as a site for ACTIV6, a double-blind study that will examine ivermectin, fluticasone furoate and fluvoxamine to determine their effectiveness in treating COVID-19.
“Through research and innovation, we’ll determine how we can most effectively treat COVID-19 while mitigating serious complications and death. We’re proud to partner with NIH and USF on this important effort,” said TGH CEO John Couris.
Tampa General will host 100 of the 15,000 participants in clinical study.